INFLAMMATION AND ATHEROGENESIS. PROGNOSTIC SIGNIFICANCE OF VASCULAR INFLAMMATION MARCER LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN ACUTE CORONARY SYNDROME
Keywords:
acute coronary syndrome, Lipoprotein-Associated Phospholipase A2, unstable plaque
Abstract
Vascular inflammation plays a key role in atherogenesis. In this regard, in cardiology for clinical evaluation of patients are widely being used biomarkers reflecting inflammation in the organism, as their increasing is associated with an increased risk of cardiovascular disease development. Determining of the level of one of these biomarkers — lipoprotein-associated phospholipase A2 (Lp-FLA2) along with the already widely used C-reactive protein promises to significantly improve the detection of high-risk patients especially in acute coronary syndrome, as well as to assess the adequacy of therapeutic strategy.
Downloads
Download data is not yet available.
References
1. Kitsiou A. N. 13N-ammonia myocardial blood flow and uptake : relation to functional outcome of asynergic regions after revascularization / A. N. Kitsiou, S. L. Bacharach, M. L. Bartlett, [et al.] // J Am Coll Cardiol. — 1999 — Vol. 33 — Р. 678—686.
2. Keng F. Y. Clinical applications of positron emission tomography in cardiology : a review / F. Y. Keng // Аnn Acad Med Singapore. — 2004. — Vol. 33. — P. 175—182.
3. Moreno P. R. Vulnerable plaque : definition, diagnosis, and treatment / P. R. Moreno // Cardiol. Clin. — 2010. — Vol. 28. — Р. 1—30.
4. Waksman R., Seruys P. W. Handbook of the vulnerable plaque / R. Waksman, P. W. Seruys // London. — 2004. — P. 1—48.
5. Лишманов Ю. Б., Чернов В. И. Радионуклидная диагностика для практических врачей / Ю. Б. Лишманов, В. И. Чернов // Томск : Издательство STT, 2004. — C. 388.
6. Сергиенко В. Б., Аншелес А. А. Молекулярные изображения в оценке атеросклероза и перфузии миокарда / В. Б. Сергиенко, А. А. Аншелес // Кардиологический вестник. — 2010. — № 2. — С. 76—83.
7. Choi Y. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans / Y. Choi, R. C. Brunken, R. A. Hawkins, [et al.] // Eur J Nucl Med. — 1993. — Vol. 20. — Р. 308—318.
8. Pearson T. A. Markers of inflammation and cardiovascular disease : application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association / T. A. Pearson, G. A. Mensah, R. W. Alexander, [et al.] // Circulation. — 2003. — Vol. 107. — Р.499—511.
9. Biasucci L.M. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases : a background paper / L. M. Biasucci // Circulation. — 2004. — Vol. 110. — e560—e567.
10. Utermann G. Lipoprotein(a). In : Scriver C. R., Beaudet A. L., Sly W. S., Valle D., eds. The Metabolic and Molecular Bases of Inherited Disease. — 8th ed. — New York : McGraw-Hill. — 2001. — Р. 2753—2787.
11. Winkler K. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors : the Ludwigshafen Risk and Cardiovascular Health Study / K. Winkler, B. R. Winkelmann, H. Scharnagl, [et al.] // Circulation. — 2005. — Vol. 111. — Р. 980—87.
12. Packard C. J. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group / C. J. Packard, D. S. O’Reilly, M. J. Caslake, [et al.] // N Engl J Med. — 2000. — Vol.343. — Р. 1148—55.
13. Blake G. J. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women / G. J. Blake, N. Dada, J. C. Fox, [et al.] // J Am Coll Cardiol. — 2001. — Vol. 38. — Р. 1302—06.
14. Ballantyne C. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study / C. Ballantyne, R. Hoogeveen, H. Bang, [et al.] // Circulation. — 2004. — Vol. 109. — Р. 837—42.
15. Koenig W. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984 / W. Koenig, C. Meisinger, G. Trischler, [et al.] // Circulation. — 2004. — Vol. 110. — Р. 1903—08.
16. Oei H. H. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke : the Rotterdam study / H. H. Oei, I. M. Van der Meer, A. Hofman, [et al.] // Circulation. — 2005. — Vol. 111. — Р.570—75.
17. Чазов Е. И. Атеросклероз / Е. И. Чазов // М. : Издательство «Медицина», 2000.
18. Сергиенко В. Б. Позитронно-эмиссионная томография в диагностике атеросклеротических бляшек у онкологических больных / В. Б. Сергиенко, Е. В. Панчковская, В. А. Манукова, М. С. Рудас // Терапевтический архив. — 2010. — № 4. — С. 45—48.
19. Rudd J. H. F. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography / J. H. F. Rudd, E. A. Warburton, T. D. Fryer, H. A. Jones, J. C. Clark, N. Antoun, P. Johnstrïm, A. P. Davenport, P. J. Kirkpatrick, [et al.] // Circulation. — 2002. — Vol. 105. — Р. 2708—2711.
20. Korngold E. C. Noninvasive imaging of apoptosis in cardiovascular disease / E. C. Korngold, F. A. Jaffer, R. W. David, E. Sosnovik // Heart Fail Rev. — 2008. — Vol. 13 — Р. 163—173.
21. Sudhir K. Lipoprotein-Associated Phospholipase A2, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease / K. Sudhir // J Clin Endocrin Metab. — 2005. — Vol. 90 (5). — Р. 3100—05.
22. Zalewski A., Macphee C. Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis / A. Zalewski, C. Macphee // Arterioscler Thromb Vasc Biol. — 2005. — Vol. 25 — 923 p.
23. Marcovina S. M. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease : recent advances and future directions / S. M. Marcovina, M. L. Koschinsky, J. J. Albers, S. Skarlatos // Clin Chem. — 2003. — Vol. 49. — Р. 1785—1796.
24. Blankenberg S. Plasma ФАТ-acetylhydrolase in patients with coronary artery disease : results of a cross-sectional analysis / S. Blankenberg, D. Stengel, H. J. Rupprecht, [et al.] // J Lipid Res. — 2003. — Vol. 44. — Р. 1381—86.
25. O’Donoghue M. Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial / M. O’Donoghue, D. A. Morrow, M. S. Sabatine, [et al.] // Circulation. — 2006. — Vol. 113. —
Р. 1745—52.
26. Gerber Y. Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community / Y. Gerber, J. P. McConnell, A. S. Jaffe, [et al.] // Arterioscler Thromb Vasc Biol. — 2006. — Vol. 26. — Р. 2517—22.
27. Braun L. T., Davidson M. H. Lp-PLA2 : A new target for statin therapy / L. T. Braun, M. H. Davidson // Curr Atheroscler Rep. — 2010 Jan. — Vol. 12 (1). — Р. 29—33.
28. Racherla S., Arora R. Utility of Lp-PLA2 in Lipid-Lowering Therapy / S. Racherla, R. Arora // Am J Ther. —2010 Jul 10.
2. Keng F. Y. Clinical applications of positron emission tomography in cardiology : a review / F. Y. Keng // Аnn Acad Med Singapore. — 2004. — Vol. 33. — P. 175—182.
3. Moreno P. R. Vulnerable plaque : definition, diagnosis, and treatment / P. R. Moreno // Cardiol. Clin. — 2010. — Vol. 28. — Р. 1—30.
4. Waksman R., Seruys P. W. Handbook of the vulnerable plaque / R. Waksman, P. W. Seruys // London. — 2004. — P. 1—48.
5. Лишманов Ю. Б., Чернов В. И. Радионуклидная диагностика для практических врачей / Ю. Б. Лишманов, В. И. Чернов // Томск : Издательство STT, 2004. — C. 388.
6. Сергиенко В. Б., Аншелес А. А. Молекулярные изображения в оценке атеросклероза и перфузии миокарда / В. Б. Сергиенко, А. А. Аншелес // Кардиологический вестник. — 2010. — № 2. — С. 76—83.
7. Choi Y. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans / Y. Choi, R. C. Brunken, R. A. Hawkins, [et al.] // Eur J Nucl Med. — 1993. — Vol. 20. — Р. 308—318.
8. Pearson T. A. Markers of inflammation and cardiovascular disease : application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association / T. A. Pearson, G. A. Mensah, R. W. Alexander, [et al.] // Circulation. — 2003. — Vol. 107. — Р.499—511.
9. Biasucci L.M. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases : a background paper / L. M. Biasucci // Circulation. — 2004. — Vol. 110. — e560—e567.
10. Utermann G. Lipoprotein(a). In : Scriver C. R., Beaudet A. L., Sly W. S., Valle D., eds. The Metabolic and Molecular Bases of Inherited Disease. — 8th ed. — New York : McGraw-Hill. — 2001. — Р. 2753—2787.
11. Winkler K. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors : the Ludwigshafen Risk and Cardiovascular Health Study / K. Winkler, B. R. Winkelmann, H. Scharnagl, [et al.] // Circulation. — 2005. — Vol. 111. — Р. 980—87.
12. Packard C. J. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group / C. J. Packard, D. S. O’Reilly, M. J. Caslake, [et al.] // N Engl J Med. — 2000. — Vol.343. — Р. 1148—55.
13. Blake G. J. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women / G. J. Blake, N. Dada, J. C. Fox, [et al.] // J Am Coll Cardiol. — 2001. — Vol. 38. — Р. 1302—06.
14. Ballantyne C. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study / C. Ballantyne, R. Hoogeveen, H. Bang, [et al.] // Circulation. — 2004. — Vol. 109. — Р. 837—42.
15. Koenig W. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984 / W. Koenig, C. Meisinger, G. Trischler, [et al.] // Circulation. — 2004. — Vol. 110. — Р. 1903—08.
16. Oei H. H. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke : the Rotterdam study / H. H. Oei, I. M. Van der Meer, A. Hofman, [et al.] // Circulation. — 2005. — Vol. 111. — Р.570—75.
17. Чазов Е. И. Атеросклероз / Е. И. Чазов // М. : Издательство «Медицина», 2000.
18. Сергиенко В. Б. Позитронно-эмиссионная томография в диагностике атеросклеротических бляшек у онкологических больных / В. Б. Сергиенко, Е. В. Панчковская, В. А. Манукова, М. С. Рудас // Терапевтический архив. — 2010. — № 4. — С. 45—48.
19. Rudd J. H. F. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography / J. H. F. Rudd, E. A. Warburton, T. D. Fryer, H. A. Jones, J. C. Clark, N. Antoun, P. Johnstrïm, A. P. Davenport, P. J. Kirkpatrick, [et al.] // Circulation. — 2002. — Vol. 105. — Р. 2708—2711.
20. Korngold E. C. Noninvasive imaging of apoptosis in cardiovascular disease / E. C. Korngold, F. A. Jaffer, R. W. David, E. Sosnovik // Heart Fail Rev. — 2008. — Vol. 13 — Р. 163—173.
21. Sudhir K. Lipoprotein-Associated Phospholipase A2, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease / K. Sudhir // J Clin Endocrin Metab. — 2005. — Vol. 90 (5). — Р. 3100—05.
22. Zalewski A., Macphee C. Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis / A. Zalewski, C. Macphee // Arterioscler Thromb Vasc Biol. — 2005. — Vol. 25 — 923 p.
23. Marcovina S. M. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease : recent advances and future directions / S. M. Marcovina, M. L. Koschinsky, J. J. Albers, S. Skarlatos // Clin Chem. — 2003. — Vol. 49. — Р. 1785—1796.
24. Blankenberg S. Plasma ФАТ-acetylhydrolase in patients with coronary artery disease : results of a cross-sectional analysis / S. Blankenberg, D. Stengel, H. J. Rupprecht, [et al.] // J Lipid Res. — 2003. — Vol. 44. — Р. 1381—86.
25. O’Donoghue M. Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial / M. O’Donoghue, D. A. Morrow, M. S. Sabatine, [et al.] // Circulation. — 2006. — Vol. 113. —
Р. 1745—52.
26. Gerber Y. Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community / Y. Gerber, J. P. McConnell, A. S. Jaffe, [et al.] // Arterioscler Thromb Vasc Biol. — 2006. — Vol. 26. — Р. 2517—22.
27. Braun L. T., Davidson M. H. Lp-PLA2 : A new target for statin therapy / L. T. Braun, M. H. Davidson // Curr Atheroscler Rep. — 2010 Jan. — Vol. 12 (1). — Р. 29—33.
28. Racherla S., Arora R. Utility of Lp-PLA2 in Lipid-Lowering Therapy / S. Racherla, R. Arora // Am J Ther. —2010 Jul 10.
How to Cite
Kopitsa, N. P., Gileva, Y. V., & Belaya, N. V. (1). INFLAMMATION AND ATHEROGENESIS. PROGNOSTIC SIGNIFICANCE OF VASCULAR INFLAMMATION MARCER LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN ACUTE CORONARY SYNDROME. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (23), 65-71. Retrieved from https://periodicals.karazin.ua/medicine/article/view/6729
Issue
Section
Reviews
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
